Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD47 IgG2σ antibody
- Development stage
- Preclinical
- Lead developer
- Janssen Research & Development
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The CD47 IgG2σ antibody is a research-stage monoclonal antibody targeting CD47 (integrin-associated protein), a 'don't eat me' signal overexpressed on tumor cells. It is engineered with a human IgG2σ (sigma) Fc domain, which is effector-silent, meaning it does not bind to Fcγ receptors. This design aims to block the CD47–SIRPα interaction to promote macrophage-mediated phagocytosis (ADCP) when combined with other opsonizing antibodies, while avoiding the hemagglutination and red blood cell depletion often associated with wild-type Fc CD47 antibodies. It has been investigated primarily in hematologic malignancies such as multiple myeloma and leukemia.
- Other names
- anti-CD47 IgG2σ antibodyCD47 IgG2sigma antibodyCD-47 IgG2sigma antibodyCD 47 IgG2sigma antibody
02
Targets
CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on CD47 IgG2σ antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD47 IgG2σ antibody.